Published by Auckland, Counties Manukau and Waitematā DHBs on 15/12/2021 7:48:29 PM.
Vaccination for 5 to 11-year-olds
Pending Medsafe and Cabinet approval, the rollout of COVID-19 vaccinations to 5 to 11-year-olds (using the child version of the Pfizer vaccine) is expected to be from mid-January 2022, using existing vaccination delivery methods, e.g. primary care, vaccination centres, pop-up events and outreach activities. Primary care will play a vital role, given existing trusted relationships with families.
More information will be provided as it becomes available.
The science behind the 5 – 11-year-olds Pfizer vaccine
If you didn’t attend the Ministry of Health’s last Primary and Community Sector webinar, this included Dr Nikki Turner of IMAC providing an update about the science behind the 5 – 11-year-olds Pfizer vaccine. This is well worth a watch – see here.
AstraZeneca – funding information
As advised by Medinz on 1 December, AstraZeneca is approved by Medsafe as a two-dose course, and as such does not require a prescription.
However, if a consumer has become hesitant to receive a second primary dose or a booster dose of the Pfizer vaccine, and wishes to receive a dose of the AstraZeneca vaccine as a substitute, this will require a prescription to reflect its “off-label” use, as well as a written consent form. Please note, patients who may have had other vaccines overseas will also need a script/consent for any AstraZeneca mixed dose course (e.g. 2 doses of Moderna and requesting an AstraZeneca booster.)
All guidance issued by the Ministry of Health must be followed, including obtaining a prescription and signed consent form where required (see attached).
Processes for claiming and payments via POAC are as follows:
The claiming conditions for this service requires there is:
See here for details of the limited number of sites offering AstraZeneca.
COVID in 2022 made easy – webinar recording
See here for the recording of NRHCC’s webinar hosted by the Goodfellow Unit on 14 December.
The webinar included the following, as well as a Q&A session at the end: